Explained variation and degrees of necessity and of sufficiency for competing risks survival data

被引:0
作者
Gleiss, Andreas [1 ]
Gnant, Michael [2 ]
Schemper, Michael [1 ]
机构
[1] Med Univ Vienna, Inst Clin Biometr, Ctr Med Data Sci, Spitalgasse 23, A-1090 Vienna, Austria
[2] Med Univ Vienna, Comprehens Canc Ctr, Vienna, Austria
关键词
competing risks; explained variation; Fine and Gray model; necessary condition; sufficient condition; PREDICTIVE ACCURACY; MODELS; COX;
D O I
10.1002/bimj.202300140
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
In this contribution, the Schemper-Henderson measure of explained variation for survival outcomes is extended to accommodate competing events (CEs) in addition to events of interest. The extension is achieved by moving from the unconditional and conditional survival functions of the original measure to unconditional and conditional cumulative incidence functions, the latter obtained, for example, from Fine and Gray models. In the absence of CEs, the original measure is obtained as a special case. We define explained variation on the population level and provide two different types of estimates. Recently, the authors have achieved a multiplicative decomposition of explained variation into degrees of necessity and degrees of sufficiency. These measures are also extended to the case of competing risks survival data. A SAS macro and an R function are provided to facilitate application. Interesting empirical properties of the measures are explored on the population level and by an extensive simulation study. Advantages of the approach are exemplified by an Austrian study of breast cancer with a high proportion of CEs.
引用
收藏
页数:17
相关论文
共 25 条
[11]  
Harrell FE, 2015, SPRINGER SER STAT, DOI 10.1007/978-3-319-19425-7
[12]   MEASURING IMPORTANCE [J].
HEALY, MJR .
STATISTICS IN MEDICINE, 1990, 9 (06) :633-637
[13]   Comparing the importance of prognostic factors in Cox and logistic regression using SAS [J].
Heinze, G ;
Schemper, M .
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, 2003, 71 (02) :155-163
[14]   On the prognostic value of survival models with application to gene expression signatures [J].
Hielscher, T. ;
Zucknick, M. ;
Werft, W. ;
Benner, A. .
STATISTICS IN MEDICINE, 2010, 29 (7-8) :818-829
[15]   Evaluating a new marker's predictive contribution [J].
Kattan, MW .
CLINICAL CANCER RESEARCH, 2004, 10 (03) :822-824
[16]   Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial [J].
Lambertini, Matteo ;
Agbor-Tarh, Dominique ;
Metzger-Filho, Otto ;
Ponde, Noam F. ;
Poggio, Francesca ;
Hilbers, Florentine S. ;
Korde, Larissa A. ;
Chumsri, Saranya ;
Werner, Olena ;
Del Mastro, Lucia ;
Caparica, Rafael ;
Moebus, Volker ;
Moreno-Aspitia, Alvaro ;
Piccart, Martine J. ;
de Azambuja, Evandro .
ESMO OPEN, 2020, 5 (06)
[17]   Using simulation studies to evaluate statistical methods [J].
Morris, Tim P. ;
White, Ian R. ;
Crowther, Michael J. .
STATISTICS IN MEDICINE, 2019, 38 (11) :2074-2102
[18]   Tutorial in biostatistics: Competing risks and multi-state models [J].
Putter, H. ;
Fiocco, M. ;
Geskus, R. B. .
STATISTICS IN MEDICINE, 2007, 26 (11) :2389-2430
[19]   Predictive accuracy and explained variation [J].
Schemper, M .
STATISTICS IN MEDICINE, 2003, 22 (14) :2299-2308
[20]   A note on quantifying follow-up in studies of failure time [J].
Schemper, M ;
Smith, TL .
CONTROLLED CLINICAL TRIALS, 1996, 17 (04) :343-346